Mark DeLong - Jan 16, 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Business & Strat Officer
Signature
/s/ David Watson, attorney-in-fact for Mark DeLong
Stock symbol
APLS
Transactions as of
Jan 16, 2024
Transactions value $
$1,526,391
Form type
4
Date filed
1/17/2024, 04:41 PM
Previous filing
Oct 24, 2023
Next filing
Jan 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +17K +32.86% $0.00 68.6K Jan 16, 2024 Direct F1
transaction APLS Common Stock Sale -$109K -1.63K -2.38% $66.81 67K Jan 16, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $1.64M +24.7K $66.30 24.7K Jan 16, 2024 Common Stock 24.7K $66.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
F2 This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024.
F3 This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.